• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Entrada Therapeutics Inc.

    11/25/25 4:29:15 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Entrada Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    29384C108

    (CUSIP Number)


    11/19/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29384C108


    1Names of Reporting Persons

    TCG Crossover GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,917,344.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,917,344.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,917,344.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I (as defined in item 2(a) below). TCG Crossover GP I (as defined in item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 38,219,232 shares of Common Stock outstanding as reported in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission (the Commission) on November 6, 2025 (the Form 10-Q).


    SCHEDULE 13G

    CUSIP No.
    29384C108


    1Names of Reporting Persons

    TCG Crossover Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,917,344.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,917,344.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,917,344.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 38,219,232 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    29384C108


    1Names of Reporting Persons

    Chen Yu
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,917,344.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,917,344.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,917,344.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 38,219,232 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Entrada Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    One Design Center Place, Suite 17-500, Boston, MA 02210
    Item 2. 
    (a)Name of person filing:

    This Joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I, and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301.
    (c)Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    29384C108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreement of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TCG Crossover GP I, LLC
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:11/25/2025
     
    TCG Crossover Fund I, L.P.
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:11/25/2025
     
    Chen Yu
     
    Signature:/s/ Craig Skaling
    Name/Title:By POA as Attorney-in-Fact
    Date:11/25/2025
    Get the next $TRDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Wentworth Kory James sold $88,932 worth of shares (8,910 units at $9.98), decreasing direct ownership by 7% to 110,026 units (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:30:41 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parmar Kush sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/18/25 4:36:30 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Entrada Therapeutics Inc.

    SCHEDULE 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/25/25 4:29:15 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Entrada Therapeutics Inc.

    SCHEDULE 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/18/25 4:38:22 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Entrada Therapeutics Inc.

    144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/14/25 4:30:42 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Entrada Therapeutics with a new price target

    ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

    12/6/24 8:19:11 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

    Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

    1/5/24 8:45:46 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Entrada Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00

    4/3/23 7:39:53 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entrada Therapeutics to Present at Upcoming Investor Conferences

    BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in LondonDipal Doshi, Chief Executive Officer, will deliver a company presentation on Tuesday, November 18, 2025, at 5:00 p.m. Greenwich Mean Time in London. 8th Annual Evercore Healthcare ConferenceDipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 12:55 p.m. Eastern Time in Miami, FL. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on th

    10/28/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

    -- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness Day on September 7, grants are designed to fund projects supporting the Duchene community on a global scale -- BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the recipients of its third annual DREAMS Grant Program. Jett Foundation (U.S.) and Parent Project aps (Italy) will each be awarded $50,000 to support programs that are working to better identify, understand and reach members of the Du

    9/5/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units ("RSUs") and options to purchase 38,850 shares of the Company's common stock to seven newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of September 1, 2025. The options have an exercise price of $5.47 per share, which is equal to the closing price of the Company's common stock on August 29, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employ

    9/2/25 4:30:00 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/12/25 5:34:18 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

    4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    6/18/25 4:32:46 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    View All

    Entrada Therapeutics Reports Second Quarter 2025 Financial Results

    -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to

    8/6/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

    BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

    6/3/25 7:00:00 AM ET
    $BIIB
    $TRDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

    āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

    9/17/24 8:30:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Entrada Therapeutics Inc.

    SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/14/24 1:22:40 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Entrada Therapeutics Inc.

    SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    6/26/24 4:54:17 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

    SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    2/14/24 4:26:22 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care